Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, U. Articles by Staeheli, P. Search for Related Content PubMed PubMed Citation Articles by Schneider, U. Articles by Staeheli, P.

 Previous Article  |  Next Article 

Journal of Virology, July 2007, p. 7293-7296, Vol. 81, No. 13
0022-538X/07/$08.00+0     doi:10.1128/JVI.02467-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

A Borna Disease Virus Vector for Expression of Foreign Genes in Neurons of Rodents

Urs Schneider,^* Andreas Ackermann, and Peter Staeheli^*

Department of Virology, University of Freiburg, 79104 Freiburg, Germany

Received 9 November 2006/ Accepted 3 April 2007

Top ABSTRACT TEXT REFERENCES

 
An expression cassette for green fluorescent protein was successfully inserted at a site near the 5' end of the genome of Borna disease virus (BDV). When introduced into a mutant virus with highly active polymerase, the foreign gene was strongly expressed in neurons of infected rats. Since BDV can establish long-term persistence in the central nervous system of rodents, it may be used to engineer efficient vectors for specific delivery of foreign genes into highly differentiated neurons.

Top ABSTRACT TEXT REFERENCES

 
Borna disease virus (BDV) is a neurotropic virus with a negative-stranded RNA genome that has adopted a noncytolytic replication cycle (2, 11). It preferentially infects neurons of the central nervous system in experimentally infected rodents as well as in natural hosts, such as horses and sheep (6, 15). We recently established a procedure for generating BDV from cloned cDNA (12, 14) that can be used to introduce defined mutations into the virus genome. It remained unclear, however, whether the compact genome of BDV has sufficient flexibility to accommodate foreign genes.

To clarify this question, we inserted a gene cassette encoding a green fluorescent protein (GFP) at four different sites of the BDV genome. The GFP gene was flanked by short sequences derived from the BDV genome that comprise transcriptional start (S1 or S3) and termination (T2 or T4) signals as indicated in Fig. 1A. Plasmids expressing the corresponding full-length viral antigenomes under the control of an RNA polymerase II promoter were transfected into human 293T cells along with expression plasmids encoding the BDV proteins N, P, and L as previously described (7). The transfected cells were subsequently cocultured with Vero cells for several weeks until newly generated virus had infected the majority of Vero cells. Successful virus propagation in Vero cells was monitored by direct observation of GFP-derived fluorescence.

View larger version (56K): [in this window] [in a new window]

FIG. 1. Successful generation of BDV with a GFP expression cassette inserted at a site near the 5' end of the genome. (A) Schematic drawing showing the main features of constructs i through iv used for generating recombinant BDV. Successful (+) and unsuccessful (–) attempts to rescue virus from the various constructs are indicated. The gene organization of wild-type (wt) virus and various insertion sites of the GFP cassette with the additionally generated transcription start (S1 or S3) and termination (T2 or T4) signals is shown. The GFP gene was derived from phrGFPII (Stratagene), encoding humanized Renilla GFP. Thick lines represent BDV genome sequences, and thin lines indicate additionally inserted sequences flanking the GFP cassette. The insertion site of the GFP cassette in the successfully rescued iv construct is shown in detail. Uppercase letters indicate BDV sequences surrounding the insertion site. Lowercase letters represent additional BDV regulatory sequences (italics) and restriction recognition sequences (underlined). The numbers indicate nucleotide positions in the BDV antigenome. Note that the GFP cassette was flanked by KpnI-PacI restriction sites in all constructs except in construct ii, where we used AatII-PacI recognition sequences to insert the GFP cassette. (B) Transcription from different constructs encoding full-length BDV antigenomes was determined by transfection of 293T cells with 4 µg of the indicated full-length BDV constructs (the nomenclature is the same as in panel A), together with 0.5 µg of pCA-N and 0.05 µg of pCA-P. pT7-BDV, which cannot be transcribed in 293T cells that lack T7 RNA polymerase, served as a background control. Three days after transfection, total RNA was extracted and 10-µg samples were treated with 2 units of Turbo DNase (Ambion) for 1 h at 37°C. Transcription products were analyzed by Northern blotting using a radiolabeled DNA probe corresponding to nucleotides 4014 to 4729 of the BDV antigenome (L gene). For a size marker, we loaded 5 µg of total RNA derived from Vero cells persistently infected with BDV. For a loading control, we show the ethidium bromide stain of the cellular 18S rRNA. (C) Northern blot analysis of 5 µg of total RNA isolated from Vero cells infected with wild-type and GFP-expressing BDV. Blots were hybridized with DNA probes specific for GFP or fragments of the BDV genome that include sequences from the N, X, and P genes or the M, G, and L genes, respectively. The identities of major transcripts are indicated. For a loading control, we show the ethidium bromide stain of the cellular 18S rRNA. (D) Spread of BDV-GFP in primary rat neurons and Vero cells visualized by fluorescence microscopy.

Several independent attempts to generate recombinant BDV carrying the GFP cassette near the 3' end of the virus genome from construct i were not successful. Similarly, no virus carrying the GFP cassette between the X/P and the M genes could be rescued from construct ii. However, virus was successfully generated when the GFP cassette was inserted near the 5' end of the virus genome (Fig. 1A). Interestingly, virus rescue was possible only when the entire 5' untranslated region (UTR) of the BDV genome remained intact at the 5' end of the recombinant genome as in construct iv. No virus was rescued if only the terminal 56 nucleotides following the T4 signal remained in the UTR as in construct iii (Fig. 1A). Analysis of polymerase II-mediated transcription from constructs i, ii, and iv suggested that reduced transcription from the transfected plasmids is not responsible for the inability of constructs i through iii to support virus rescue (Fig. 1B). Furthermore, alignment of the BDV leader and trailer sequences did not provide evidence for a paramyxovirus-like B-box sequence that might regulate BDV transcription and replication. Thus, the lack of rescue from constructs i and iii can probably not be explained by accidental disruption of this putative regulatory element near the ends of the BDV genome. Northern blot analysis revealed normal levels of the various viral RNAs (Fig. 1C, left and middle) and easily detectable levels of GFP RNA (Fig. 1C, right) in Vero cells infected with the GFP-expressing virus (BDV-GFP) obtained from construct iv. We further observed bright fluorescence in cultured primary rat neurons and Vero cells infected with BDV-GFP (Fig. 1D). Careful analysis of viral growth in Vero cells showed severely reduced propagation of BDV-GFP compared to that for wild-type virus (Fig. 2A). Surprisingly, the growth kinetics of BDV and BDV-GFP in Vero cells infected at a high multiplicity of infection (MOI; 0.25) did not reveal different levels of viral transcripts at 66 h postinfection (Fig. 2B). Since BDV spreads only very slowly in cell culture, synthesis of viral RNA under these experimental conditions is probably restricted to cells infected with the inoculum. Thus, attenuation of BDV-GFP appears to be mainly a consequence of impaired viral cell-to-cell spread rather than impaired viral genome transcription and replication. It should be noted that we cannot exclude the possibility that although too subtle for detection by our assay, small differences in RNA synthesis can result in delayed propagation of BDV-GFP if the cells are infected at a low MOI (Fig. 2A).

View larger version (30K): [in this window] [in a new window]

FIG. 2. Growth characteristics of wild-type (wt) and GFP-expressing BDV in Vero cells. (A) Cultures infected with either virus at an MOI of 0.01 per cell were split twice weekly, and the proportion of infected cells was determined by immunostaining for the BDV N protein as described previously (7). (B) Vero cells (4 x 105) were infected at an MOI of 0.25 per cell with the indicated virus for 2 h at 37°C. The cells were then washed with 1 ml of phosphate-buffered saline, and fresh growth medium was added. At the indicated hours postinfection (h p.i.), total RNA was extracted and 10-µg samples were subjected to Northern blotting. Viral RNA was detected using a DNA probe corresponding to nucleotides 976 to 1749 of the BDV antigenome (X/P gene). The identities of major viral transcripts are indicated. For a loading control, we show the ethidium bromide stain of the cellular 18S rRNA. n.i., not infected.

Injection of 2,000 focus-forming units of BDV-GFP into the brains of 4-week-old Lewis rats did not result in neurological disease within 47 days of infection (Table 1). Immunohistochemical analysis (10) revealed only a few virus-positive cells in the brains of these animals (data not shown). By contrast, injection of the same dose of recombinant wild-type virus resulted in fulminate virus growth in rat brains (data not shown) and neurological disease within 20 to 21 days postinfection (Table 1). These results demonstrated that the GFP-expressing virus is strongly attenuated.

View this table: [in this window] [in a new window]

TABLE 1. Frequency of disease in 4-week-old Lewis rats infected with different BDV variants

During an independent study, which will be published elsewhere, we observed that two mutations in the L gene greatly enhance the growth kinetics of BDV. The mutant L protein (designated LRD) carries an arginine residue instead of leucine at position 1116 and aspartic acid instead of asparagine at position 1398. To determine whether these growth-promoting mutations would also enhance the propagation of BDV-GFP, we introduced these mutations into the L gene of construct iv as shown in Fig. 1. Transfection of the modified iv construct yielded a replication-competent virus, termed BDV-LRD-GFP, which replicated in Vero cells almost as efficiently as wild-type BDV-LRD virus (Fig. 3A), indicating the clearly improved propagation efficacy of this virus. The finding that a more active polymerase drastically improved the fitness of BDV-GFP is not in conflict with the growth kinetics presented in Fig. 2B. In fact, a scenario in which impaired cell-to-cell spread of BDV-GFP is overcome once the polymerase activity reaches a certain threshold level provides a plausible explanation for the fact that propagation of BDV-GFP is more strongly impaired than that of BDV-LRD-GFP in comparison to those of their respective wild-type counterparts.

View larger version (23K): [in this window] [in a new window]

FIG. 3. A BDV mutant carrying two mutations in the L gene and the GFP cassette near the 5' end of the genome (LRD-GFP) replicates well in cultured cells and rat hippocampus neurons. (A) Growth analysis of Vero cells was done as described in the legend to Fig. 1. (B) Four-week-old Lewis rats were infected by the intracerebral route with 2,000 focus-forming units of BDV-LRD-GFP. After signs of neurological disease appeared at around 26 days postinfection, the animals were killed and cryosections of the brain were examined by fluorescence analysis.

Virus stocks prepared from Vero cells infected with BDV-LRD-GFP exhibited normal infectivities, and infection of 4-week-old Lewis rats with BDV-LRD-GFP induced neurological disease in six of seven animals (Table 1). The time between infection and onset of disease was slightly longer (average, 26 days) than for control animals infected with BDV-LRD lacking a foreign expression cassette (average, 18 days). Analysis of brains from diseased animals for cells expressing GFP revealed particularly strong staining of neurons in the dentate gyrus and CA3 region of the hippocampus formation (Fig. 3B), which are known to contain high concentrations of viral antigen after natural and experimental infections of animals with BDV (1).

This study demonstrated that foreign genes can be inserted into the genome of BDV and that a foreign gene was expressed well in neurons of infected rats. It suggests that BDV vectors can be used to study the effects of therapeutic genes in neurons of rodents. BDV vectors may represent a good alternative to classical transgenic approaches for mice and can be used in place of other viral vectors with no intrinsic preference for neurons.

The potential use of BDV as vector for experimental gene delivery is complicated by the fact that this virus can induce neurological disease in rodents (4). However, since BDV-induced disease is mediated by CD8 T cells (16), disease can be prevented by several means, including suppression of the antiviral immune response by appropriate drugs and the use of animals that lack CD8 T cells. BDV vectors may be considered for use in mice because this problem is less severe in mice than in rats. Most mouse strains fail to mount an efficient antiviral response against BDV and, consequently, remain healthy in spite of viral persistence in the central nervous system (5).

Out of three insertion sites analyzed, only the insertion site close to the 5' end of the BDV genome yielded a replication-competent viral vector. Interestingly, the insertion of GFP at this site was tolerated only when the complete UTR remained intact at the 5' end of the BDV genome, indicating that the sequence between the termination codon of the L gene and T4 might be important for the regulation of viral replication. It remains unclear why the insertion of the foreign gene at the two other positions failed to yield replication-competent virus. A simple interpretation of these results is that both the region preceding the first gene and the third intergenic region contain unrecognized regulatory elements that may not be destroyed. Alternatively, the relative expression levels of the various genes of BDV may be in a delicate balance, which is lost if an additional transcription unit is inserted. Evidence in favor of this view comes from previous observations that nonbalanced expression of the N and P genes has drastic negative effects on BDV polymerase activity (3, 8, 13). We noted that insertion of the GFP gene even at the tolerated site near the 5' end of the virus genome resulted in strong virus attenuation. Interestingly, the attenuating effect of foreign gene insertion was much less pronounced in a BDV mutant with intrinsically more active polymerase. Although the molecular basis of this observation remains unclear, it has important practical consequences. Unlike wild-type virus, the mutant represents a robust vector for transgene delivery approaches in rodents.

Altogether, our study is the basis for future work aimed at developing BDV into a vector system for experimental gene therapy approaches in rodents. It further paves the way for new genetic approaches to answering questions related to the complex biology of BDV. We demonstrate in the accompanying paper by Poenisch and coworkers (9) that the essential functions of the BDV-X gene can be complemented by ectopic expression of the X protein with the BDV vector system.

 
We thank Annette Ohnemus and Rosita Frank for excellent technical assistance, Arnold Martin and Sandra Wille for performing virus growth analyses, and Marion Poenisch, Martin Schwemmle, Georg Kochs, and Otto Haller for comments on the manuscript.

This work was supported by grants SCHN 765/1-5 and STA 338/8-1 from the Deutsche Forschungsgemeinschaft.

 
* Corresponding author. Mailing address: Department of Virology, University of Freiburg, Hermann-Herder-Strasse 11, D-79104 Freiburg, Germany. Phone: 49-761-203-6579. Fax: 49-761-203-5350. E-mail for Urs Schneider: urs.schneider{at}uniklinik-freiburg.de. E-mail for Peter Staeheli: peter.staeheli{at}uniklinik-freiburg.de

Published ahead of print on 11 April 2007.

Top ABSTRACT TEXT REFERENCES

 

1
1. de la Torre, J. C. 2002. Bornavirus and the brain. J. Infect. Dis. 186(Suppl. 2):S241-S247.[CrossRef][Medline]
2
2. de la Torre, J. C. 2006. Reverse-genetic approaches to the study of Borna disease virus. Nat. Rev. Microbiol. 4:777-783.[CrossRef][Medline]
3
3. Geib, T., C. Sauder, S. Venturelli, C. Hassler, P. Staeheli, and M. Schwemmle. 2003. Selective virus resistance conferred by expression of Borna disease virus nucleocapsid components. J. Virol. 77:4283-4290.[Abstract/Free Full Text]
4
4. Gonzalez-Dunia, D., C. Sauder, and J. C. de la Torre. 1997. Borna disease virus and the brain. Brain Res. Bull. 44:647-664.[CrossRef][Medline]
5
5. Hallensleben, W., M. Schwemmle, J. Hausmann, L. Stitz, B. Volk, A. Pagenstecher, and P. Staeheli. 1998. Borna disease virus-induced neurological disorder in mice: infection of neonates results in immunopathology. J. Virol. 72:4379-4386.[Abstract/Free Full Text]
6
6. Ludwig, H., L. Bode, and G. Gosztonyi. 1988. Borna disease: a persistent virus infection of the central nervous system. Prog. Med. Virol. 35:107-151.[Medline]
7
7. Martin, A., P. Staeheli, and U. Schneider. 2006. RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J. Virol. 80:5708-5715.[Abstract/Free Full Text]
8
8. Perez, M., A. Sanchez, B. Cubitt, D. Rosario, and J. C. de la Torre. 2003. A reverse genetics system for Borna disease virus. J. Gen. Virol. 84:3099-3104.[Abstract/Free Full Text]
9
9. Poenisch, M., S. Wille, A. Ackermann, P. Staeheli, and U. Schneider. 2007. The X protein of Borna disease virus serves essential functions in the viral multiplication cycle. J. Virol. 81:7297-7299.[Abstract/Free Full Text]
10
10. Sauder, C., and P. Staeheli. 2003. Rat model of Borna disease virus transmission: epidemiological implications. J. Virol. 77:12886-12890.[Abstract/Free Full Text]
11
11. Schneemann, A., P. A. Schneider, R. A. Lamb, and W. I. Lipkin. 1995. The remarkable coding strategy of borna disease virus: a new member of the nonsegmented negative strand RNA viruses. Virology 210:1-8.[CrossRef][Medline]
12
12. Schneider, U. 2005. Novel insights into the regulation of the viral polymerase complex of neurotropic Borna disease virus. Virus Res. 111:148-160.[CrossRef][Medline]
13
13. Schneider, U., M. Naegele, P. Staeheli, and M. Schwemmle. 2003. Active Borna disease virus polymerase complex requires a distinct nucleoprotein-to-phosphoprotein ratio but no viral X protein. J. Virol. 77:11781-11789.[Abstract/Free Full Text]
14
14. Schneider, U., M. Schwemmle, and P. Staeheli. 2005. Genome trimming: a unique strategy for replication control employed by Borna disease virus. Proc. Natl. Acad. Sci. USA 102:3441-3446.[Abstract/Free Full Text]
15
15. Stitz, L., T. Bilzer, J. A. Richt, and R. Rott. 1993. Pathogenesis of Borna disease. Arch. Virol. Suppl. 7:135-151.[Medline]
16
16. Stitz, L., B. Dietzschold, and K. M. Carbone. 1995. Immunopathogenesis of Borna disease. Curr. Top. Microbiol. Immunol. 190:75-92.[Medline]

---

Journal of Virology, July 2007, p. 7293-7296, Vol. 81, No. 13
0022-538X/07/$08.00+0     doi:10.1128/JVI.02467-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Poenisch, M., Wille, S., Schneider, U., Staeheli, P. (2009). Second-site mutations in Borna disease virus overexpressing viral accessory protein X. J. Gen. Virol. 90: 1932-1936 [Abstract] [Full Text]  
• Poenisch, M., Wille, S., Ackermann, A., Staeheli, P., Schneider, U. (2007). The X Protein of Borna Disease Virus Serves Essential Functions in the Viral Multiplication Cycle. J. Virol. 81: 7297-7299 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, U. Articles by Staeheli, P. Search for Related Content PubMed PubMed Citation Articles by Schneider, U. Articles by Staeheli, P.